Navigation Links
Longevinex exerts greater influence over genes than resveratrol
Date:12/27/2010

Las Vegas, NV (Dec. 24, 2010) - Three weeks of oral resveratrol or Longevinex ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study four microRNA optimally regulated by Longevinex and two optimally by plain resveratrol.

A pre-conditioning effect with resveratrol and Longevinex had already been demonstrated in prior studies where these small molecules activate antioxidant defenses (nitric oxide, heme oxygenase, adenosine) prior to a heart attack, thus limiting damage in the event of an abrupt halt in the delivery of oxygenated blood to the heart.

This newly published study in the PLoS ONE (Public Library of Science) journal sought to compare and contrast the gene switching pattern for both plain resveratrol and resveratrol in a matrix with other small molecules (Longevinex) following an induced blockage of circulation in excised animal hearts.

MicroRNA explained

MicroRNA is a mechanism within living cells that switches genes. MicroRNA's are short segments of RNA that turn off gene protein-making machinery (called gene expression) when microRNA meshes with messenger RNA.

First thought to exert a minor influence over the human genome (library of genes), microRNA's are now more fully recognized as "the genome's guiding hand" - a fundamental regulator of over 90% of human genes. MicroRNA appear to exert a stronger influence over the human genome than two other known mechanisms (methylation and histone modification) of gene regulation. MicroRNAs exceed the biological action of most drugs, which are largely targeted at single genes, while microRNAs regulate complex networks of genes, there is feverish work being done to create drugs that influence microRNA.

Beyond gene switching

Of course, the objective is to produce health benefits, not just switch genes. Indeed, these small molecules did just that. Plain resveratrol and Longevinex both protected heart tissues and reduced the size of a heart attack, as measured by the amount of scar tissue (fibrosis).

Longevinex reduced the size of a heart attack (from ~35% without treatment to ~20% scar tissue with treatment) in a superior manner to plain resveratrol (from ~35% to ~24% scar tissue), and reduced death of heart muscle cells (cardiomyocytes) from ~17% without treatment to ~9% with Longevinex (48% reduction in cell death), compared to a decline from ~17% to ~12% with plain resveratrol (20% reduction in cell death).

While plain resveratrol modestly improved the pumping pressure of the heart (from ~75 to ~90 millimeters of mercury pressure; 20% improvement), Longevinex doubled heart pumping pressure (from ~70 to ~140 millimeters of mercury pressure; 100% improvement) compared to no treatment at the two-hour point following an experimentally-induced heart attack.

Also at the two-hour point, Longevinex improved blood flow in the aorta (first blood vessel outside the pumping side of the heart) from ~15 milliliters per minute without treatment to ~26 milliliters per minute (73% improvement), while resveratrol improved blood flow from ~14 milliliters per minute without treatment to ~21 milliliters per minute (50% improvement).

Back to microRNA switching

Upon analysis, it became clear that Longevinex exerted the greatest influence over the top 25 significantly differentiated microRNA's in rodent heart tissue. Longevinex exceeded the effect of resveratrol in 15 of the 25 microRNA's.

Comparative analysis of three key microRNA (microRNA 20b, 21, 539) are instructive.

Longevinex profoundly down-regulated microRNA 20b (-1366-fold) compared to plain resveratrol (-189-fold), a microRNA that exerts control over a gene (hypoxia inducing factor, or HIF-1 alpha) that adapts malignant cells to a low oxygen environment. MicroRNA 20b also exhibits control over growth factors (such as vascular endothelial growth factor, aka VEGF). The strong silencing (switching off) of HIF-1 alpha via microRNA 20b would be desirable, for example, to inhibit formation of new blood vessels that feed tumors and which invade the retina at the back of the eyes.

Prior to an induced heart attack, microRNA 21 was tremendously up-regulated (up 391.4-fold) by resveratrol and Longevinex (up 760.9-fold), was lowered considerably after a heart attack (-4.0), then returned to up-regulation following a heart attack by resveratrol (up 61.5) and Longevinex (up 59.3), which suggests protective pre-conditioning prior to the event.

MicroRNA 539 exhibited the highest level of up-regulation (214 fold) following a heart attack, which suggests a protective response. Resveratrol diminished this response (down from 214-fold to 172.4 fold) while Longevinex further enhanced this microRNA response, from 214-fold to 314.6-fold increase. MicroRNA 539 controls of a number of genes involved in healing heart tissue following a heart attack.


'/>"/>

Contact: Bill Sardi
bsardi@aol.com
909-596-9507
Resveratrol Partners LLC, dba LONGEVINEX
Source:Eurekalert

Related biology news :

1. Over 1,000 species discovered in the Greater Mekong in past decade
2. Genetic differences between yeasts greater than those between humans and chimpanzees
3. Lower increases in global temps could lead to greater impacts than previously thought, study finds
4. Scots and Irish at greater risk of drink-related death, study shows
5. Food insecurity can lead to greater weight gain and complications during pregnancy
6. Small mammals -- and rest of food chain -- at greater risk from global warming than thought
7. Children born after assisted reproduction at greater risk of congenital malformations
8. Greater food insecurity from recession poses increased risk to low income individuals with diabetes
9. New report suggests why risk for sudden infant death syndrome is greater in babies of mothers who smoke
10. Faster water flow means greater diversity of invertebrate marine life
11. Late-preterm babies at greater risk for problems later in childhood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
Breaking Biology Technology: